Healthcare provider profile · identity verified

Keith Freeman, DO

Internal Medicine · GREER, SC · NPI 1003357948

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	372	133
Amlodipine Besylate	Amlodipine Besylate	254	91
Levothyroxine Sodium	Levothyroxine Sodium	235	77
Losartan Potassium	Losartan Potassium	224	71
Rosuvastatin Calcium	Rosuvastatin Calcium	213	72
Omeprazole	Omeprazole	207	72
Lisinopril	Lisinopril	183	69
Gabapentin	Gabapentin	155	55
Metoprolol Succinate	Metoprolol Succinate	154	57
Pantoprazole Sodium	Pantoprazole Sodium	146	53
Albuterol Sulfate Hfa	Albuterol Sulfate	127	56
Tamsulosin Hcl	Tamsulosin Hcl	125	46
Trazodone Hcl	Trazodone Hcl	121	44
Fluticasone Propionate	Fluticasone Propionate	101	55
Lorazepam	Lorazepam	96	25
Meloxicam	Meloxicam	92	39
Famotidine	Famotidine	91	39
Pravastatin Sodium	Pravastatin Sodium	91	32
Montelukast Sodium	Montelukast Sodium	87	31
Duloxetine Hcl	Duloxetine Hcl	86	31
Simvastatin	Simvastatin	86	31
Metformin Hcl	Metformin Hcl	81	30
Hydrochlorothiazide	Hydrochlorothiazide	79	31
Sertraline Hcl	Sertraline Hcl	75	26
Carvedilol	Carvedilol	74	30
Jardiance	Empagliflozin	74	25
Zolpidem Tartrate	Zolpidem Tartrate	73	25
Allopurinol	Allopurinol	68	27
Escitalopram Oxalate	Escitalopram Oxalate	67	23
Ezetimibe	Ezetimibe	65	23
Nitroglycerin	Nitroglycerin	63	44
Alprazolam	Alprazolam	61	16
Clopidogrel	Clopidogrel Bisulfate	59	22
Metformin Hcl Er	Metformin Hcl	59	22
Celecoxib	Celecoxib	58	25
Furosemide	Furosemide	58	24
Synthroid	Levothyroxine Sodium	58	suppressed
Methylprednisolone	Methylprednisolone	55	49
Ozempic	Semaglutide	55	15
Metoprolol Tartrate	Metoprolol Tartrate	50	21
Bupropion Xl	Bupropion Hcl	46	15
Venlafaxine Hcl Er	Venlafaxine Hcl	44	11
Baclofen	Baclofen	42	suppressed
Diclofenac Sodium	Diclofenac Sodium	42	23
Clonazepam	Clonazepam	41	12
Fluoxetine Hcl	Fluoxetine Hcl	41	16
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	41	14
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	37	28
Ciprofloxacin Hcl	Ciprofloxacin Hcl	36	27
Eliquis	Apixaban	36	18
Finasteride	Finasteride	33	12
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	33	13
Prednisone	Prednisone	32	22
Promethazine Hcl	Promethazine Hcl	31	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	30	14
Esomeprazole Magnesium	Esomeprazole Magnesium	30	13
Olmesartan Medoxomil	Olmesartan Medoxomil	30	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	30	26
Valacyclovir	Valacyclovir Hcl	30	11
Citalopram Hbr	Citalopram Hydrobromide	28	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	27	suppressed
Potassium Chloride	Potassium Chloride	27	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	26	suppressed
Atenolol	Atenolol	24	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	24	12
Sumatriptan Succinate	Sumatriptan Succinate	24	suppressed
Xarelto	Rivaroxaban	24	suppressed
Nebivolol Hcl	Nebivolol Hcl	23	suppressed
Azithromycin	Azithromycin	22	21
Benazepril Hcl	Benazepril Hcl	22	suppressed
Tramadol Hcl	Tramadol Hcl	22	suppressed
Nystatin	Nystatin	21	14
Ondansetron Hcl	Ondansetron Hcl	21	12
Tizanidine Hcl	Tizanidine Hcl	21	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	21	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	20	20
Diazepam	Diazepam	20	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	20	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	20	18
Farxiga	Dapagliflozin Propanediol	20	suppressed
Glimepiride	Glimepiride	20	suppressed
Glipizide	Glipizide	20	suppressed
Januvia	Sitagliptin Phosphate	19	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	19	suppressed
Temazepam	Temazepam	19	suppressed
Valsartan	Valsartan	19	suppressed
Lovastatin	Lovastatin	18	suppressed
Nifedipine Er	Nifedipine	18	suppressed
Spironolactone	Spironolactone	18	suppressed
Pregabalin	Pregabalin	17	suppressed
Propranolol Hcl	Propranolol Hcl	17	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	17	suppressed
Ipratropium Bromide	Ipratropium Bromide	16	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	16	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	16	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	16	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	15	suppressed
Cefdinir	Cefdinir	15	14
Folic Acid	Folic Acid	15	suppressed
Acyclovir	Acyclovir	14	suppressed
Donepezil Hcl	Donepezil Hcl	14	suppressed
Alendronate Sodium	Alendronate Sodium	13	suppressed
Amlodipine-Valsartan	Amlodipine Besylate/Valsartan	13	suppressed
Buspirone Hcl	Buspirone Hcl	13	suppressed
Colestipol Hcl	Colestipol Hcl	13	suppressed
Hydralazine Hcl	Hydralazine Hcl	13	suppressed
Naloxone Hcl	Naloxone Hcl	13	12
Doxazosin Mesylate	Doxazosin Mesylate	12	suppressed
Ketoconazole	Ketoconazole	12	suppressed
Levofloxacin	Levofloxacin	12	12
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	12	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	12	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	11	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	11	suppressed
Epinephrine	Epinephrine	11	suppressed
Fenofibrate	Fenofibrate	11	suppressed
Midodrine Hcl	Midodrine Hcl	11	suppressed
Mirtazapine	Mirtazapine	11	suppressed
Repatha Sureclick	Evolocumab	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error